Nonepithelial Malignancies of the Breast

Soybir, Gürsel

doi:10.1007/978-3-319-26012-9_27

Cited by 2 publications

(2 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In more than 30% of breast cancers over the expression of the HER2/neu gene has been observed (4). HER2 is a growth factor receptor produced by erbB-2 gene and has tyrosine kinase activity in the cells (5). Regarding the critical role of HER2 and MUC1 in the diagnosis of breast cancer, choosing the appropriate method for determining their expression levels in cancer cells is very important (1,6).…”

Section: Introductionmentioning

confidence: 99%

Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer

et al. 2019

View full text Add to dashboard Cite

Background: Among all types of malignant diseases, breast cancer has worldwide importance because of the high mortality rate in women aged fewer than 50 in the developing countries. Identification of immunogenic antigens and the generation of specific antibodies against cancer cells are the most successful strategies for early detection and effective treatment of breast cancer. Objectives: In the current study, a chimeric protein consisting of two specific surface antigens, MUC1 and HER2, were used for the production of chitosan nanoparticles and evaluated as a vaccine candidate. Methods: The pET-28a expression vector harboring the HER2-MUC1 gene was constructed. Expression of the protein in E. coli BL21 (DE3) was induced using IPTG. The recombinant HER2-MUC1 (HM) protein was purified using a Ni-NTA column and confirmed by western blotting. Chitosan nanoparticles containing the target protein were prepared and the lymphocytes viability was evaluated using MTT assay. Results: The expression of the recombinant protein with molecular weight of 40 kDa was confirmed using SDS-PAGE and Western blotting. The electric charge and the size of the nanoparticles were determined and verified by a Zeta Sizer device. The evaluation of IgG and IgA titration suggested that inducing humoral and mucosal immune responses by administering nanoparticles containing the chimeric protein. Analysis of cell-mediated immunity showed that the chimeric HM protein could induce specific splenocyte proliferation in immunized mice. Conclusions: It seems that HM nanoparticles can be utilized as a vaccine candidate for inducing the cellular and humoral immune response against breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Occasionally, inflammatory breast cancer is also diagnosed which is a very aggressive form of breast cancer that blocks the lymph nodes in the skin and causes swelling [42]. Other rare forms of female breast cancers include breast sarcomas which initiate from the fatty tissues and breast lymphomas which starts from the lymph vessels near the breast [43].…”

Section: Female Breast Cancermentioning

confidence: 99%

Investigations into optical biosensors in visible-NIR wavelength band for disease detection applications

Pae¹

View full text Add to dashboard Cite

In the latest published results from Global Burden of Disease (GBD) in 2017, the top two contributors to the disease burden which requires the most urgent attention are Alzheimer's Disease (AD) and female breast cancer. As AD is a neurological disorder with unknown causes, it is almost impossible to adopt any preventive measures. Additionally, current medical tools are unable to reverse the effects of AD. Hence, the best approach is to detect the early onset of AD so that measures can be implemented early to halt or slow down its progress. However, existing techniques for the early detection of AD primarily focus on using neuroimaging which may be too expensive to conduct regularly. Therefore, there is an urgent need for a low-cost method for the early detection of AD. In the case of female breast cancer, despite being the most diagnosed form of cancer, the data also have shown that it has very promising survival rates when the cancer is detected and treated in the early stages. However, the effectiveness of existing breast cancer detection techniques is hugely limited by the low uptake of the screening program. This could be due to the lack of awareness or misconception regarding breast cancer and due to the perceived hassle of having to go for regular screening at periodic intervals. Hence, there is a need to explore alternative breast cancer screening methods that are more hasslefree.A biosensor is a promising candidate in this context, which could provide a low-cost and hassle-free approach for the screening of diseases such as AD and female breast cancer.Electrochemical biosensors are well-established and have already been commercialised such as blood glucose monitors. However, such biosensors typically have low sensitivity which could not be used to accurately diagnose diseases. With the recent improvement

show abstract

Nonepithelial Malignancies of the Breast

Cited by 2 publications

References 109 publications

Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer

Construction and Structural Assessment of Nanocapsule Containing HER2-MUC1 Chimeric Protein as a Candidate for a Vaccine Against Breast Cancer

Investigations into optical biosensors in visible-NIR wavelength band for disease detection applications

Contact Info

Product

Resources

About